Summary & Overview
CPT 87253: Viral Identification After Tissue Culture
CPT code 87253 captures confirmatory virology work in which an analyst applies additional tests (such as neutralization) to specifically identify a virus isolated by tissue culture. This code matters nationally because confirmatory identification supports accurate diagnosis, public health surveillance, infection control decisions, and appropriate patient management when initial culture results are inconclusive or require specification.
Key payers commonly involved in coverage and reimbursement for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a succinct explanation of the clinical and laboratory context for 87253, practical notes on where the service is delivered, and what stakeholders typically consider when evaluating claims for specialized virology identification.
The publication summarizes benchmarks and billing context for confirmatory virology testing, highlights clinical scenarios that prompt additional identification steps after tissue culture isolation, and outlines policy-relevant topics such as laboratory service classification and payer coverage considerations. Data not provided in the input (for example, utilization rates, reimbursement amounts, and associated taxonomies or ICD-10 mappings) are noted as unavailable.
Billing Code Overview
CPT code 87253 describes laboratory procedures in which a lab analyst performs additional virology tests (for example, neutralization) to specifically identify a virus from a patient specimen that was previously isolated and provisionally identified using tissue culture methodology.
-
Service type: Specialized virology identification testing involving confirmatory serologic or neutralization assays performed after initial virus isolation.
-
Typical site of service: Clinical virology laboratories or reference laboratories with tissue culture capability and confirmatory testing workflows.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A virology laboratory receives a nasopharyngeal specimen from an inpatient with an acute viral syndrome. The specimen is processed and inoculated into appropriate cell lines for tissue culture; a laboratory analyst observes cytopathic effect and performs initial identification using immunofluorescence or rapid antigen techniques. To achieve definitive typing and confirm the viral agent, a second analyst performs additional, specific assays such as neutralization testing or targeted serologic neutralization to identify the virus strain isolated in culture. Typical workflow: specimen accessioning → culture inoculation and incubation → primary identification by the first analyst → referral to a virology specialist or second analyst for neutralization or other confirmatory tests (87253) → result verification and reporting to the ordering clinician. Typical site of service is an outpatient or hospital clinical virology laboratory within a medical center or reference laboratory. A realistic patient scenario: a hospitalized adult with fever, respiratory distress, and radiographic infiltrates whose nasopharyngeal swab yields a cytopathic effect in tissue culture; the lab performs neutralization to specifically identify influenza A subtype or adenovirus serotype for infection control and epidemiologic reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component of the test if the physician/lab professional provides interpretation separate from the technical component. |